Chemomab Therapeutics Ltd.

NasdaqCM:CMMB Stock Report

Market Cap: US$41.9m

Chemomab Therapeutics Management

Management criteria checks 3/4

Chemomab Therapeutics' CEO is Adi George, appointed in Jan 2011, has a tenure of 3.83 years. total yearly compensation is $330.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 3.01% of the company’s shares, worth $1.26M. The average tenure of the management team and the board of directors is 1.9 years and 3.8 years respectively.

Key information

Adi George

Chief executive officer

US$330.0k

Total compensation

CEO salary percentage100.0%
CEO tenure14yrs
CEO ownership3.0%
Management average tenure1.9yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Will Chemomab Therapeutics (NASDAQ:CMMB) Spend Its Cash Wisely?

Jan 10
Will Chemomab Therapeutics (NASDAQ:CMMB) Spend Its Cash Wisely?

Chemomab Therapeutics (NASDAQ:CMMB) Is In A Good Position To Deliver On Growth Plans

Sep 19
Chemomab Therapeutics (NASDAQ:CMMB) Is In A Good Position To Deliver On Growth Plans

Chemomab Therapeutics - ADR GAAP EPS of -$0.027

Aug 12

Chemomab Therapeutics: Pioneering Anti-CCL24 MAb For Fibrotic Diseases

Dec 03

CEO Compensation Analysis

How has Adi George's remuneration changed compared to Chemomab Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$14m

Jun 30 2024n/an/a

-US$15m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$330kUS$330k

-US$24m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$435kUS$298k

-US$28m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$488kUS$249k

-US$12m

Sep 30 2021n/an/a

-US$9m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$6m

Dec 31 2020US$325kUS$229k

-US$6m

Compensation vs Market: Adi's total compensation ($USD330.00K) is below average for companies of similar size in the US market ($USD645.01K).

Compensation vs Earnings: Adi's compensation has been consistent with company performance over the past year.

CEO

Adi George (42 yo)

14yrs

Tenure

US$330,000

Compensation

Dr. Adi Mor George, Ph.D. serves as Chief Executive Officer of Chemomab Therapeutics Ltd. since June 01, 2023. She is the Co-Founder of Chemomab Therapeutics Ltd.and has been its Chief Scientific Officer...

Leadership Team

NamePositionTenureCompensationOwnership
Adi George
Co-Founder14yrsUS$330.00k3.01%
$ 1.3m
Sigal Fattal
Chief Financial Officer1.6yrsUS$322.00k0.024%
$ 10.1k
Matthew Frankel
Chief Medical Officer & VP of Drug Development2.2yrsUS$850.00k0%
$ 0
Barbara Lindheim
Consulting Vice President of Investor & Public Relationsno datano datano data
Jack Lawler
Senior VP of Global Clinical Development Operationsless than a yearno datano data

1.9yrs

Average Tenure

53yo

Average Age

Experienced Management: CMMB's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Adi George
Co-Founder3.8yrsUS$330.00k3.01%
$ 1.3m
Neil Cohen
Independent Director4.8yrsUS$123.00k0.75%
$ 313.5k
Nissim Darvish
Independent Chairman3.8yrsUS$123.00k0.0064%
$ 2.7k
Alan Moses
Independent Director3.8yrsUS$119.00k0%
$ 0
Scott L. Friedman
Member of Scientific Advisory Boardno datano datano data
Claude Nicaise
Independent Director3.8yrsUS$123.00k0%
$ 0
Massimo Pinzani
Member of Scientific Advisory Boardno datano datano data
Arun Sanyal
Member of Scientific Advisory Boardno datano datano data
Jill Quigley
Independent Director2.6yrsUS$38.00k0%
$ 0
Marco Matucci-Cerinic
Member of Scientific Advisory Boardno datano datano data
Dinesh Khanna
Member of Scientific Advisory Boardno datano datano data
Francesco Del Galdo
Member of Scientific Advisory Boardno datano datano data

3.8yrs

Average Tenure

59.5yo

Average Age

Experienced Board: CMMB's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 15:35
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chemomab Therapeutics Ltd. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Michael OkunewitchMaxim Group
Jeffrey JonesOppenheimer & Co. Inc.